X 22

Drug Profile

X 22

Alternative Names: X-22

Latest Information Update: 25 Jun 2017

Price : $50

At a glance

  • Originator 22nd Century
  • Developer 22nd Century; Queen Mary University of London; University of Auckland
  • Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Smoking withdrawal

Most Recent Events

  • 22 Jun 2017 22nd Century receives guidance from the US FDA on phase III trials for Smoking withdrawal
  • 22 Jun 2017 22nd Century and Heracles Pharmaceuticals plans to initiate phase III trials for Smoking withdrawal in USA in the first half of 2018
  • 08 Sep 2015 No recent reports on development identified - Phase-III for Smoking withdrawal in New Zealand (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top